Australia's most trusted
source of pharma news
Friday, 04 April 2025
Posted 3 April 2025 AM
Stanford University researchers have hailed MSD’s recently discontinued shingles vaccine Zostavax as a potential intervention for dementia with Australian experts weighing in on their findings.
Results published in the journal Nature overnight suggest that Zostavax may reduce the risk of dementia by up to 20 per cent over seven years following vaccination.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.